Invivoscribe Technologies Announces Companion Diagnostic Agreement
April 28, 2015 08:07 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Apr 28, 2015) - Invivoscribe® Technologies, Inc., a company with international experience commercializing in vitro diagnostic tests and developing companion...
Invivoscribe(R) Launches Four CE-Marked NGS-Based LymphoTrack(R) Dx Assays
April 21, 2015 08:07 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Apr 21, 2015) - Invivoscribe Technologies, Inc. (IVS) announced today the commercial release of four CE-marked LymphoTrack® Dx next-generation sequencing (NGS)...
Genection Announces Launch of MyAML(TM), a Next Generation Sequencing (NGS) Assay for Acute Myeloid Leukemia
March 17, 2015 06:00 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) - Genection™, Inc., a subsidiary of Invivoscribe Technologies®, Inc., announced today that it has launched MyAML™, a CLIA validated next...
Invivoscribe FLT3 Method Patent Claims Upheld
July 16, 2013 00:01 ET
|
Invivoscribe
SAN DIEGO, CA--(Marketwired - Jul 16, 2013) - Invivoscribe Technologies, Inc. ("Invivoscribe") has successfully defended the method claims at the core of international patents covering FLT3...
Invivoscribe Prevails in German District Court (FLT3 Patent Infringement Action)
May 14, 2013 00:01 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - May 14, 2013) - MLL Münchner Leukämielabor GmbH ("MLL") Laboratories has been found guilty of patent infringement in a matter involving FLT3 testing patent...
Takara Bio Grants Patent License to Invivoscribe Technologies for FLT3-ITD Testing in Japan
December 05, 2012 08:38 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwire - Dec 5, 2012) - Invivoscribe Technologies, Inc. (San Diego, California) announced today that it has entered into an agreement with Takara Bio, Inc. (Otsu, Shiga, Japan)...